Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
European Journal of Haematology|July 28, 2010
Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinibUlla Olsson-Strömberg, Monica Hermansson, Tuija Lundán, et al.
Leukemia Research|January 9, 2007
Gene expression analysis identifies a genetic signature potentially associated with response to alpha-IFN in chronic phase CML patientsAnette Hagberg, Ulla Olsson-Strömberg, Ulrika Wickenberg-Bolin, et al.
Leukemia Research|October 7, 2016
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuliStina Söderlund, Lisa Christiansson, Inger Persson, et al.
Blood|May 4, 2011
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreJoerg Hasford, Michele Baccarani, Verena Hoffmann, et al.
Blood|May 15, 2007
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 studyOliver Ottmann, Hervé Dombret, Giovanni Martinelli, et al.
British Journal of Haematology|August 30, 2002
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML GroupUlla Axdorph, Leif Stenke, Gunnar Grimfors, et al.
European Journal of Haematology|December 31, 2013
Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular responsePerttu Koskenvesa, Anna Kreutzman, Peter Rohon, et al.
Immunology|April 6, 2011
Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitroCamilla A Lindqvist, Lisa H Christiansson, Ingrid Thörn, et al.
American Journal of Hematology|October 6, 2018
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITYRüdiger Hehlmann, Jorge E Cortes, Teresa Zyczynski, et al.
Leukemia Research|January 18, 2003
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemiaAstrid Gruber, Magnus Björkholm, Lorentz Brinch, et al.
Pageof 4